Purple Biotech shares are trading lower by 28% during Tuesday's session. The company announced a $2.8 million offering. Purple Biotech's Phase 2 trial of CM24 in metastatic PDAC patients showed ...
Purple Biotech PPBT, a clinical-stage oncology company, reported positive final results from the mid-stage study of its lead candidate, CM24, for treating pancreatic ductal adenocarcinoma (“PDAC ...
it received an extension of 180 calendar days from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) to regain compliance with the Nasdaq’s minimum $1.00 bid price ...
This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.
The intraday chart, the last-five real-time quotes and sales data. Real-time stock quotes can be used to help inform investors when researching potential investment opportunities.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...